Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Salmeterol: a novel, long-acting beta 2-agonist

J M Meyer1, C L Wenzel, W A Kradjan

  • 1College of Pharmacy, University of Illinois at Chicago 60680.

The Annals of Pharmacotherapy
|December 1, 1993
PubMed
Summary

Salmeterol, a long-acting beta 2-agonist, effectively treats asthma, particularly nocturnal and allergen-induced types, with a 12-hour duration. Further research is needed on its long-term effects and anti-inflammatory role.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Stress indicators in minorities with multiple sclerosis.

Multiple sclerosis and related disorders·2023
Same author

Phosphate-solubilizing bacteria associated with proteoid roots of seedlings of waratah [Telopea speciosissima (Sm.) R.Br.].

The New phytologist·2021
Same author

CERKL is upregulated in cutaneous squamous cell carcinoma and maintains cellular sphingolipids and resistance to oxidative stress.

The British journal of dermatology·2021
Same author

CERKL is Upregulated in Cutaneous Squamous Cell Carcinoma and Maintains Cellular Sphingolipids and Resistance to Oxidative Stress.

The British journal of dermatology·2020
Same author

Lubiprostone for treatment-resistant constipation associated with clozapine use.

Acta psychiatrica Scandinavica·2014
Same author

Significance of saguaro cactus alkaloids in ecology ofDrosophila mettleri, a soil-breeding, cactophilic drosophilid.

Journal of chemical ecology·2013

Area of Science:

  • Pharmacology
  • Respiratory Medicine
  • Clinical Therapeutics

Background:

  • Salmeterol is a selective, long-acting beta 2-agonist used for asthma management.
  • It exhibits potent in vitro anti-inflammatory effects and prolonged receptor occupancy, contributing to its extended duration of action.

Purpose of the Study:

  • To review the clinical pharmacology, pharmacokinetics, efficacy, and adverse effects of salmeterol.
  • To evaluate salmeterol's effectiveness in treating various asthma types, including exercise-induced, nocturnal, and allergen-induced asthma.

Main Methods:

  • A comprehensive MEDLINE search identified relevant English-language publications on salmeterol.
  • Clinical efficacy was assessed through open and controlled trials, with effectiveness evaluated using randomized controlled trials.

Main Results:

  • Salmeterol demonstrated superior efficacy compared to albuterol in treating asthma, including exercise and allergen-induced forms.
  • Its 12-hour duration of action is advantageous for nocturnal asthma, though a delayed onset of action is a potential drawback.
  • Reported adverse effects were mild, including headache, tremor, and palpitations.

Conclusions:

  • Salmeterol is an effective beta 2-agonist for asthma treatment.
  • Further investigation is required concerning its long-term disease control effects, the significance of its anti-inflammatory activity, and its potential role as a rescue medication.

Related Experiment Videos